The IL-2 therapeutic landscape is expanding dramatically, driven by intensifying cancer therapy demands, groundbreaking autoimmune research, and crucial CAR-T/NK cell treatment integration. Market leaders feature Novartis (Proleukin), Alkermes, NeoImmuneTech, Eli Lilly, and Nektar Therapeutics.
Uncover comprehensive IL-2 market evaluation and predictions:
https://www.delveinsight.com/i....nfographics/interleu
إعجاب
علق
شارك
